Blockade of bulky lymphoma‐associated CD55 expression by RNA interference overcomes resistance to complement‐dependent cytotoxicity with rituximab

Recently, anti‐CD20 (rituximab) and anti‐Her2/neu (trastuzumab) antibodies have been developed and applied to the treatment of malignant lymphoma and breast cancer, respectively. However, bulky lymphoma is known to be resistant to rituximab therapy, and this needs to be overcome. Fresh lymphoma cell...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer science 2006-01, Vol.97 (1), p.72-79
Hauptverfasser:	Terui, Yasuhito, Sakurai, Takuma, Mishima, Yuko, Mishima, Yuji, Sugimura, Natsuhiko, Sasaoka, Chino, Kojima, Kiyotsugu, Yokoyama, Masahiro, Mizunuma, Nobuyuki, Takahashi, Shunji, Ito, Yoshinori, Hatake, Kiyohiko
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antineoplastic agents Biological and medical sciences CD55 Antigens - genetics CD55 Antigens - metabolism Cell Line, Tumor Complement System Proteins - drug effects Complement System Proteins - immunology Drug Resistance, Neoplasm Gene Expression Regulation, Neoplastic Humans Immunotherapy Lymphoma - drug therapy Lymphoma - genetics Lymphoma - immunology Lymphoma - pathology Medical sciences Original Pharmacology. Drug treatments Rituximab RNA Interference RNA, Small Interfering - genetics RNA, Small Interfering - metabolism Tumors
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Recently, anti‐CD20 (rituximab) and anti‐Her2/neu (trastuzumab) antibodies have been developed and applied to the treatment of malignant lymphoma and breast cancer, respectively. However, bulky lymphoma is known to be resistant to rituximab therapy, and this needs to be overcome. Fresh lymphoma cells were collected from 30 patients with non‐Hodgkin's lymphoma, the expression of CD20 and CD55 was examined by flow cytometry, and complement‐dependent cytotoxicity (CDC) assays were carried out. Susceptibility to CDC with rituximab was decreased in a tumor size‐dependent manner (r = –0.895, P
ISSN:	1347-9032 1349-7006
DOI:	10.1111/j.1349-7006.2006.00139.x